期刊文献+

沙利度胺联合替莫唑胺杀伤U251胶质瘤细胞机制的体外研究 被引量:4

Study on mechanism of thalidomide combined with temozolomide to suppress proliferation of U251 glioma cell in vitro
下载PDF
导出
摘要 目的对沙利度胺联合替莫唑胺杀伤U251胶质瘤细胞的机制进行体外研究,为制订沙利度胺与替莫唑胺联合化疗方案提供理论依据。方法经体外培养的人胶质瘤细胞系U251分别接受替莫唑胺(100 μmol/L)、沙利度胺(100 μg/L)、替莫唑胺与沙利度胺联合治疗,噻唑蓝(MTT)法检测不同抗肿瘤药物处理组肿瘤细胞增殖活性;流式细胞术分析细胞增殖周期;检测经吖啶橙标记的酸性囊性细胞器数目;原位末端标记(TUNEL)法观察肿瘤细胞凋亡情况;Western blotting法检测肿瘤自噬及凋亡相关蛋白表达变化。结果与替莫唑胺和沙利度胺单药治疗相比,替莫唑胺与沙利度胺联合治疗对U251细胞生长的抑制更为明显(均P=0.000),且可诱导肿瘤细胞周期阻滞于G_0~G_1期,以及发生凋亡和自噬。两药联合治疗后,U251细胞微管相关蛋白1轻链3和Caspase-3表达水平高于替莫唑胺组和沙利度胺组(均P=0.000)。结论沙利度胺联合替莫唑胺治疗U251细胞可以上调自噬及凋亡相关基因表达水平,同时诱导凋亡及自噬性死亡,从而达到对U251胶质瘤细胞的杀伤作用。 Objective To provide a more reasonable regimen of temozolomide and thalidomide, and study the mechanism of these 2 drugs in inhibiting the proliferation and growth of U251 glioma cell in vitro. Methods Human glioma cell line U251 was cultured in vitro and divided into different treatment groups for 3 d: temozolomide group (100 μmol/L), thalidomide group (100 μg/L), temozolomide (100 μmol/L) with thalidomide group (100 μg/L) and vehicle control group. After different treatment for 3 d, 3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was adopted for the determination of cell viability, and cell cycle was analysed by flow cytometry. After labeled with acridine orange (AO), autophagy vesicles were quantitatively detected by flow cytometry. TdT-mediated dUTP-biotin nick end labeling (TUNEL) was employed in observing and detecting the apoptosis of treated cells. Western blotting was used in examining the autophagy and apoptosis-related proteins. Results Compared with the 2 drugs used alone, temozolomide with thalidomide imposed more obvious inhibition on tumor cell growth (P = 0.000, for all). Combination of 2 drugs induced tumor cell cycle arrest in G0-Gl. Both of autophagic and apoptotic cell death could be induced by temozolomide with thalidomide in U251. In two-drug treatment group, the expression of autophagy-related microtubule-associated protein I light chain 3 (MAP1LC3) and apoptosis-related Caspase-3 was significantly higher in transcriptional level in comparing with single drug treatment group (P = 0,000, for all). Conclusion Temozolomide combined with thalidomide may induce 2 types of programmed cell death-apoptotic and autophagic cell death by up-regulating the expression of related genes in U251 glioma cell, thereby, the combination of these 2 drugs may suppress the proliferation and growth of U251 glioma cell in vitro.
出处 《中国现代神经疾病杂志》 CAS 2010年第5期533-539,共7页 Chinese Journal of Contemporary Neurology and Neurosurgery
基金 国家自然科学基金资助项目(项目编号:30571904) 国家自然科学基金资助项目(项目编号:30772228)
关键词 神经胶质瘤 替莫唑胺 细胞凋亡 自噬 流式细胞术 细胞 培养的 体外 研究 Glioma Apoptosis Autophagy Flow cytometry Cells,
  • 相关文献

参考文献2

二级参考文献11

  • 1Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms: an update on the muhidisciplinary management of malignant glioma. J Oncologist, 2006, 11:165-180.
  • 2Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev, 2001, 35:161-204.
  • 3Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gent O^6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res, 1999, 59:793-797.
  • 4Liegi ME, Liu L, Herman JG, et al. Correlation of O6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol, 2008, 26:4189-4199.
  • 5Kanzawa T, Germano IM, Komata T, et al. Role of autophagy in temozolomide- induced cytotoxicity for malignant glioma cells. Cell Death Differ, 2004, 11:448-457.
  • 6Hampson R, Humbert O, Macpherson P, et al. Mismatch repair defect and O6-methylguanine-DNA methyltransferase expression in acquired resistance to methylating agents in human cells. J Biol Chem, 1997, 272:28596-28606.
  • 7Paus C, Murat A, Stupp R, et al. Role of MGMT and clinical applications in brain tumours. Bull Cancer, 2007, 94:769-773.
  • 8Balana C, Carrato C, Ramirez J, et al. Concordance and clinical value of the MGMT promoter methylation pattern in tissue with paired serum and MGMT promoter methylation pattern in a series of glioblastoma (GB) patients. J Clin Oncol, 2008, 26 Suppl:98.
  • 9李晓兴,王之敏,左剑玲,许期年,王秀云,陶承.替莫唑胺诱导的人脑胶质瘤耐药细胞系的建立及其耐药性逆转[J].苏州大学学报(医学版),2007,27(2):169-171. 被引量:6
  • 10杨学军,江涛,陈忠平.治愈恶性胶质瘤从理想到现实:临床医生还应做些什么[J].中国现代神经疾病杂志,2008,8(5):373-375. 被引量:14

共引文献24

同被引文献61

  • 1袁苗苗,张春春,王亚华,朱佳,轩亚茹,应雪.替莫唑胺壳聚糖微球的构建及对C6细胞抑制作用的评价[J].农垦医学,2014,36(1):17-21. 被引量:1
  • 2陈步东,杨玉山.替莫唑胺治疗颅内恶性胶质瘤疗效观察[J].中国现代神经疾病杂志,2004,4(4):220-223. 被引量:9
  • 3Athanassiou H, Synodinou M, Maragoudakis E, et al.Randomized phase II study of temozolmide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol, 2005, 23:2372-2377.
  • 4Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 2009, 10:434-435.
  • 5Weller M, Schmidt C, Roth W, et al. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology, 1997, 48:1704-1709.
  • 6Gorman AM, Hirt UA, Orrenius S, et al. Dexamethasone pretreatment interferes with apoptotic death in glioma ceils. Neuroscience, 2000, 96:417-425.
  • 7Benedetti S, Pirola B, Poliani PL, et al. Dexamethasone inhibits the anti- tumor effect of interleukin 4 on rat experimental gliomas. Gene Ther, 2003, 10:188-192.
  • 8Sur P, Sribnick EA, Patel S J, et al. Dexamethasone decreases temozolomide- induced apoptosis in human gliobastoma T98G cells. Glia, 2005, 50:160-167.
  • 9Das A, Banik NL, Ray SK. Methylprednisolone and indomethacin inhibit oxidative stress mediated apoptosis in rat C6 glioblastoma cells. Neurochern Res, 2007, 32:1849-1856.
  • 10Das A, Banik NL, Ray SK. Modulatory effects of acetazolomide and dexamethasone on temozolomide- mediated apoptosis in human glioblastoma T98G and U87MG cells. Cancer Invest, 2008, 26:352-358.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部